Helix Biopharma Corp.
Announces fiscal Year-End Results 2024
Helix Biopharma Corp.
Announces Frankfurt Market Trading
Who We Are?
We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.
DOS47 – Confirmed Mechanism of Action